MARKET

TBIO

TBIO

TRANSLATE BIO, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.61
+0.87
+4.62%
Opening 13:16 06/22 EDT
OPEN
18.74
PREV CLOSE
18.74
HIGH
19.69
LOW
18.33
VOLUME
679.70K
TURNOVER
--
52 WEEK HIGH
34.64
52 WEEK LOW
11.91
MARKET CAP
1.47B
P/E (TTM)
-66.1437
1D
5D
1M
3M
1Y
5Y
Covid-19 Showed mRNA Vaccines Work. Translate Bio, Sanofi, Are Testing One for Flu.
marketwatch.com · 4h ago
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21)
Benzinga · 5h ago
Sanofi, Translate Bio Start Trial Evaluating Flu Vaccine
marketwatch.com · 7h ago
Sanofi, Translate Bio launch Phase 1 trial of mRNA influenza vaccine
Sanofi Pasteur, the vaccines global business unit of Sanofi (SNY) and Translate Bio (TBIO) have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza. The
Seekingalpha · 8h ago
UPDATE 2-European shares propped up by commodities, Powell speech in focus
reuters.com · 9h ago
UPDATE 1-European shares slip as inflation debate keeps bears on prowl
reuters.com · 9h ago
Sanofi and Translate Bio start clinical trial for mRNA flu vaccine
reuters.com · 12h ago
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
-- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise --
GlobeNewswire · 12h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TBIO. Analyze the recent business situations of TRANSLATE BIO, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TBIO stock price target is 24.25 with a high estimate of 28.00 and a low estimate of 19.00.
EPS
Institutional Holdings
Institutions: 197
Institutional Holdings: 69.66M
% Owned: 92.59%
Shares Outstanding: 75.23M
TypeInstitutionsShares
Increased
62
5.26M
New
24
2.18M
Decreased
41
4.14M
Sold Out
27
1.01M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.49%
Key Executives
President
Everett Sutherland
Chief Executive Officer/Director
Ronald Renaud
Chief Financial Officer
Brendan Smith
Chief Operating Officer/Secretary
Paul Burgess
Chief Accounting Officer
Robert Prentiss
Chief Scientific Officer
Richard Wooster
Other
Ann Barbier
Independent Director
Daniella Beckman
Independent Director
George Demetri
Independent Director
Jean-Francois Formela
Independent Director
Owen Hughes
Independent Director
Robert Meyer
Independent Director
Robert Plenge
No Data
  • All
  • Financials
  • Insiders
More
About TBIO
Translate Bio, Inc. is a messenger RNA, or mRNA, therapeutics company. The Company is developing medicines to treat diseases caused by protein or gene dysfunction. The Company is using its proprietary mRNA therapeutic platform, or MRT platform, and it create mRNA that encodes functional proteins. The mRNA is delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. The MRT product candidate for the lung, MRT5005, is designed to address the underlying cause of CF by delivering mRNA encoding fully functional CFTR protein to the lung epithelial cells through nebulization.

Webull offers kinds of Translate Bio Inc stock information, including NASDAQ:TBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TBIO stock methods without spending real money on the virtual paper trading platform.